Skip Nav Destination
Close Modal
1-20 of 1365 Search Results for
company
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Journal Article
J Health Polit Policy Law (2013) 38 (3): 505–544.
Published: 01 June 2013
...Denis G. Arnold; James L. Oakley As the pharmaceutical industry lobbies European regulators to permit direct-to-consumer advertising (DTCA) of prescription drugs in the European Union, we found that five leading companies violated industry-developed and -promulgated standards for ethical...
Journal Article
J Health Polit Policy Law (2002) 27 (1): 5–30.
Published: 01 February 2002
... insurance. In an extensive survey of health care purchasing practices among Fortune 500 companies we found that major companies are not using the managed competition approach to health care purchasing. Instead, most of the companies surveyed are purchasing health care in the same way as they do other inputs...
Journal Article
J Health Polit Policy Law (1987) 12 (1): 53–76.
Published: 01 February 1987
... and format, minimum rates of return, sale of these policies related to disclosure requirements, consumer information activities, and penalties for agent and company abuse. This paper examines the impact of specific regulations on the ratio of the expected policy benefits per premium dollars and on the number...
Journal Article
J Health Polit Policy Law (2024) 49 (2): 249–268.
Published: 01 April 2024
... that allegedly obtain improper payment from federal programs. Methods: The authors searched the Department of Justice website for press releases published between 2006 and 2022 that announced fraud actions brought against drug companies. They then used the World Health Organization's Anatomical Therapeutic...
FIGURES
| View All (8)
Journal Article
J Health Polit Policy Law (1982) 7 (1): 80–95.
Published: 01 February 1982
.... There is a large, stable segment of the prepaid industry that developed as a result of private sector and community concern long before the federal HMO Act of 1973, and it is their initiatives along with increasing investment activity by insurance companies and management companies in particular, that will serve...
Journal Article
J Health Polit Policy Law (2008) 33 (6): 1031–1055.
Published: 01 December 2008
..., and qualitative interviews with policy makers. The first lesson for the United States is that the new Dutch health insurance model may not control costs. To date, consumer premiums are increasing, and insurance companies report large losses on the basic policies. Second, regulated competition is unlikely to make...
Journal Article
J Health Polit Policy Law (2009) 34 (6): 979–1010.
Published: 01 December 2009
...Sandra Adamini; Hans Maarse; Esther Versluis; Donald W. Light After lengthening the duration of patents to twenty years in 1984, the pharmaceutical industry has turned to data exclusivity as a major vehicle for extending market protection, even after patents expire. Such protections give companies...
Journal Article
J Health Polit Policy Law (2006) 31 (3): 497–510.
Published: 01 June 2006
... collectively with insurance companies, as a means of counteracting insurers' monopsony power. It is not clear that health insurers possess significant monopsony power. Even if they do, bestowing monopoly power on physicians will not necessarily improve matters. Active antitrust enforcement in insurance markets...
Journal Article
J Health Polit Policy Law (2021) 46 (2): 235–276.
Published: 01 April 2021
... and no policy advocacy lay a maze of hidden channels companies used to advance their interests. Working through those channels, Coca-Cola influenced China's science making and policy making during every phase in the policy process, from framing the issues to drafting official policy. Conclusions: Though China...
Journal Article
J Health Polit Policy Law (2022) 47 (4): 453–472.
Published: 01 August 2022
..., while opioid prescriptions for older adults increased ninefold between 1995 and 2010. Methods: We reviewed internal pharmaceutical industry documents released in legal discovery to determine how companies targeted these groups to increase prescribing and sales. This review included an analysis...
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2022) 47 (6): 691–708.
Published: 01 December 2022
... purchase commitments (APCs), wherein a payer commits to purchase a certain quantity of medications at lower prices, offer payers incentives to increase access to high-value medications while also offering companies guaranteed revenue. This article discusses the use of subscription models, a type of APC...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 879–895.
Published: 01 December 2022
... the debate over whether companies should receive more restricted rights to products originating with government funding. This article traces the history leading to the enactment of the Bayh-Dole Act and critically assesses its strengths and weaknesses as well as unresolved questions concerning its scope...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 673–690.
Published: 01 December 2022
.... The authors examined how much of Medicaid programs' accelerated approval spending is attributable to products that have demonstrated clinical benefits versus those that have not. Their findings provide support for states' concerns that pharmaceutical companies often fail to complete their required...
FIGURES
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (1997) 22 (2): 427–465.
Published: 01 April 1997
... companies, and private insurers. (2) Private payment distributes overall system costs according to use (or expected use) of services, costing wealthier and healthier people less than finance from (income-related) taxation. (3) Wealthy and unhealthy people can purchase (real or perceived) better access...
Journal Article
J Health Polit Policy Law (1997) 22 (2): 595–631.
Published: 01 April 1997
...Jonathan B. Oberlander A primary goal of many Medicare reform proposals is to move program beneficiaries into managed care plans operated by private insurance companies. Advocates contend that managed care based reforms? This article summarizes the claims that are made for and against incorporating...
Journal Article
J Health Polit Policy Law (1993) 18 (3): 695–722.
Published: 01 June 1993
... in this fashion, and statutory health insurance should be added now. All or most groups would be required to join. Financing would come from social security payroll taxes, supplemented by government subsidies. Basic acute care services would be equally available to all. The existing insurance companies would...
Journal Article
J Health Polit Policy Law (1992) 17 (4): 847–868.
Published: 01 August 1992
... of safety, quality, and efficacy of new drugs; to multinational and domestic companies competing in national and international markets; and to varied interest groups of professionals and consumers organized along national and multinational lines. We review the history of the EC's policy proposals, examine...
Journal Article
J Health Polit Policy Law (1992) 17 (2): 329–352.
Published: 01 April 1992
... of social accommodation rather than health. To succeed, Philip Morris's effort had to be widely accepted and noncontroversial. Proponents of the ordinance countered with controversy to undermine the campaign and expose the company's intentions. The controversy made the established health organizations...
Journal Article
J Health Polit Policy Law (2008) 33 (5): 943–963.
Published: 01 October 2008
...Christy A. Rentmeester; Robert I. Garis How ought we determine whether businesses in the health care sector profit fairly? One class of companies in the health care sector, pharmacy benefit managers (PBMs), deserves special consideration. We describe two specific revenue-generating practices...
Journal Article
J Health Polit Policy Law (1990) 15 (2): 357–385.
Published: 01 April 1990
... demand for drug treatment in the 1970s and 1980s has produced a new drug treatment system that suffers from many of the policy problems common to the rest of health care. Drug abuse in the workplace has resulted in much wider coverage of substance abuse services by insurance companies and HMOs...
1
